The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.
Nasser H. Hanna
No relevant relationships to disclose
Rolf Kaiser
Employment or Leadership Position - Boehringer Ingelheim
Richard N. Sullivan
No relevant relationships to disclose
Osvaldo Rudy Aren
No relevant relationships to disclose
Myung-Ju Ahn
No relevant relationships to disclose
Beatrice Tiangco
No relevant relationships to disclose
Zanete Zvirbule
No relevant relationships to disclose
Carlos H. Barrios
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Ahmet Demirkazik
No relevant relationships to disclose
Birgit Gaschler-Markefski
Employment or Leadership Position - Boehringer Ingelheim
Isabelle Voccia
Employment or Leadership Position - Boehringer Ingelheim
Jose Barrueco
Employment or Leadership Position - Boehringer Ingelheim
Joo-Hang Kim
Research Funding - Boehringer Ingelheim